SCHEMBL887848

SCHEMBL887848

NCC#Cc1n[nH]c2ncnc(N)c12

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 13/20 0.36
PIK3CA P42336 13/20 0.36
PIK3CB P42338 13/20 0.36
PIK3CG P48736 13/20 0.36
PRKDC P78527 13/20 0.36
SGK1 O00141 1/20 0.35
MEN1 O00255 1/20 0.35
DYRK3 O43781 1/20 0.35
EIF4E P06730 1/20 0.35
EIF2AK2 P19525 1/20 0.35
MTOR P42345 1/20 0.35
CSNK1D P48730 1/20 0.35
KMT2A Q03164 1/20 0.35
BRSK2 Q8IWQ3 1/20 0.35
AURKB Q96GD4 1/20 0.35
MKNK1 Q9BUB5 1/20 0.35
MKNK2 Q9HBH9 1/20 0.35
ABL1 P00519 2/20 0.34
SRC P12931 2/20 0.34
RET P07949 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL887826 0.86 AHCY (0.38) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL2908006 0.83 TLR7 (0.35) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL887796 0.80 PIK3CD (0.41) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL22924982 0.78 ABL1 (0.32) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL887847 0.76 PIK3CD (0.44) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL1845744 0.76 PIK3CD (0.39) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL19260192 0.75 RET (0.50) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL18797650 0.75 EGFR (0.51) DYRK3AURKBMKNK2ABL1SRC
SCHEMBL20142878 0.75 PIK3CD (0.38) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC
SCHEMBL19414367 0.74 RET (0.40) PIK3CDPIK3CAPIK3CBPIK3CGPRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1687609-B1 FLUORESCENT PROBES FOR DNA DETECTION BY HYBRIDIZATION WITH IMPROVED SENSITIVITY AND LOW BACKGROUND EPOCH BIOSCIENCES INC (US) 2014-12-10 EP claimed
US-8067177-B2 Amplification methods EPOCH BIOSCIENCES, INC. (US) 2011-11-29 US claimed
US-20110027780-A1 AMPLIFICATION METHODS ELITECHGROUP MDX LLC 2011-02-03 US claimed
US-7759126-B2 Real-time linear detection probes: sensitive 5′-minor groove binder-containing probes for amplification (or PCR) analysis ELITECH HOLDING B.V. (NL) 2010-07-20 US claimed
US-7723038-B2 Amplification methods ELITECH HOLDING B.V. (NL) 2010-05-25 US claimed
US-7553643-B2 Method for amplifying target nucleic acid sequences using a primer comprising an AP endonuclease-cleavable linker EPOCH BIOSCIENCES, INC. (US) 2009-06-30 US claimed
US-20080293586-A1 FLUORESCENT PROBES FOR DNA DETECTION BY HYBRIDIZATION WITH IMPROVED SENSITIVITY AND LOW BACKGROUND EPOCH BIOSCIENCES, INC. (US) 2008-11-27 US claimed
US-20080248474-A1 AMPLIFICATION METHODS EPOCH BIOSCIENCES, INC (US) 2008-10-09 US claimed
US-7381818-B2 Fluorescent probes containing 5′-minor groove binder, fluorophore and quenching moieties and methods of use thereof EPOCH BIOSCIENCES, INC. (US) 2008-06-03 US claimed
US-7205105-B2 Real-time linear detection probes: sensitive 5′-minor groove binder-containing probes for PCR analysis EPOCH BIOSCIENCES, INC. (US) 2007-04-17 US claimed
EP-1687609-A2 FLUORESCENT PROBES FOR DNA DETECTION BY HYBRIDIZATION WITH IMPROVED SENSITIVITY AND LOW BACKGROUND Epoch Biosciences, Inc. (US) 2006-08-09 EP claimed
US-20050214797-A1 Fluorescent probes for DNA detection by hybridization with improved sensitivity and low background EPOCH BIOSCIENCES, INC (US) 2005-09-29 US claimed
WO-2005043127-A2 FLUORESCENT PROBES FOR DNA DETECTION BY HYBRIDIZATION WITH IMPROVED SENSITIVITY AND LOW BACKGROUND EPOCH BIOSCIENCES, INC. (US) 2005-05-12 WO claimed
US-20030175728-A1 Real-time linear detection probes: sensitive 5'-minor groove binder-containing probes for PCR analysis EPOCH BIOSCIENCES, INC. (US) 2003-09-18 US claimed
US-12571025-B2 Isolation and detection of DNA from plasma EXACT SCIENCES CORPORATION (US) 2026-03-10 US disclosed
EP-4655415-A1 COMPOSITIONS AND METHODS FOR SIGNAL-AMPLIFIED FLAP CLEAVAGE ASSAYS Exact Sciences Corporation (US) 2025-12-03 EP disclosed
US-12385087-B2 Normalization of polymerase activity EXACT SCIENCES CORPORATION (US) 2025-08-12 US disclosed
US-20030235822-A1 Systems and methods for predicting oligonucleotide melting temperature (TmS) EPOCH BIOSCIENCES, INC. 2003-12-25 US disclosed
US-20030224359-A1 TMLEVELING METHODS EPOCH BIOSCIENCES, INC. 2003-12-04 US disclosed
US-20030175728-A1 Real-time linear detection probes: sensitive 5'-minor groove binder-containing probes for PCR analysis EPOCH BIOSCIENCES, INC. (US) 2003-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293586-A1 FLUORESCENT PROBES FOR DNA DETECTION BY HYBRIDIZATION WITH IMPROVED SENSITIVITY AND LOW BACKGROUND SSBP1, DDB1, DNA2 PIK3CD 4646/4885PIK3CA 4403/4885PIK3CB 3883/4885
US-20030175728-A1 Real-time linear detection probes: sensitive 5'-minor groove binder-containing probes for PCR analysis RNGTT, DCLRE1B, CNBP PIK3CD 4285/4885PIK3CA 3942/4885PIK3CB 2889/4885
US-20050214797-A1 Fluorescent probes for DNA detection by hybridization with improved sensitivity and low background SSBP1, DDB1, DNA2 PIK3CD 4646/4885PIK3CA 4403/4885PIK3CB 3883/4885
US-20030224359-A1 TMLEVELING METHODS PTBP3, RNGTT, DTYMK PIK3CD 4726/4885PIK3CA 3455/4885PIK3CB 3405/4885
US-12571025-B2 Isolation and detection of DNA from plasma DNMT3A, DNMT1, DNMT3B PIK3CD 375/4885PIK3CA 845/4885PIK3CB 764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.